Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15865MR)

This product GTTS-WQ15865MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15865MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15464MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ9419MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ7972MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15207MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ5790MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ15181MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ15538MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ15731MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VX-15
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW